Last reviewed · How we verify
NCT02962388
The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second Line
Phase 2, PHASE3 trial testing Anagrelide in Essential Thrombocythemia in 13 participants. Terminated before completion.
28 June 2021
Quick facts
| Lead sponsor | French Innovative Leukemia Organisation |
|---|---|
| Phase | Phase 2, PHASE3 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 13 |
| Start date | 3 January 2017 |
| Primary completion | 28 June 2021 |
| Estimated completion | 28 June 2021 |
| Sites | 1 location across France |
Drugs / interventions tested
- Anagrelide (ANAGRELIDE) — full drug profile →
- Ruxolitinib (JAKAVI®) — full drug profile →
- IFNα/ PegIFNα — full drug profile →
Conditions studied
- Essential Thrombocythemia — all drugs for Essential Thrombocythemia →
Sponsor
French Innovative Leukemia Organisation — full company profile →
Who can join
Adults 18 to 74, any sex, with Essential Thrombocythemia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Prospective national multicenter randomized open label phase IIb RUXBETA trial.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT02962388
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Anagrelide
Trials testing the same drug.
- NCT06079879 — A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thromb · Phase 3 · recruiting
- NCT04285086 — Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Into · Phase 3 · active not recruiting
- NCT03123588 — Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intole · Phase 2 · terminated
- NCT00202644 — A Study of Anagrelide and Hydroxyurea in High-Risk Essential Thrombocythemia Patients · Phase 4 · completed
Other recruiting trials for Essential Thrombocythemia
Currently open trials in the same condition.
- NCT06661915 — A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs) · Phase 2 · recruiting
- NCT06734637 — Efficacy and Safety of Peginterferon in ET and PV. · NA · recruiting
- NCT06456346 — Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007) · Phase 3 · recruiting
- NCT06361641 — Functional and Phenotypic Characterization of Monocytes in Myeloproliferative Syndromes · NA · recruiting
- NCT06378437 — A Study of GLB-001 in Patients With Myeloid Malignancies · Phase 1 · recruiting
Other French Innovative Leukemia Organisation trials
Trials by the same sponsor.
- NCT07007052 — Phase II Study Evaluating the Efficacy and Safety of the Combination of Tagraxofusp and Venetoclax in Treatment-naive Bl · Phase 2 · not yet recruiting
- NCT06547866 — Study Evaluating the Efficacy and Tolerance of a Zanubrutinib and BGB-11417 Combination in Patients Previously Treated f · Phase 2 · not yet recruiting
- NCT06377579 — OBServatory of Compassionate Use of IVOsidenib in France for Patients With Acute Myeloid Leukemia · recruiting
- NCT06263387 — Results From a French Temporary Utilization Authorization of First-line Acute Myeloid Leukemia (AML) Patients Ineligible · recruiting
- NCT06186648 — Evaluation of Treatment by Glofitamab in Combination With Rituximab or Obinutuzumab Plus CHOP in Patients With RIchter S · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02962388 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by French Innovative Leukemia Organisation
- Last refreshed: 29 June 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02962388.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing